作者: Rachel K. Peterson , Tara McKeown , Uri Tabori , Ute Bartels , Eric Bouffet
DOI: 10.1002/PBC.28690
关键词:
摘要: Clinical trials of MEK inhibitors are underway in pediatric low-grade glioma (PLGG) with BRAF oncogene mutations and recurrent/refractory disease. Cognitive behavioral impacts inhibitors, such as trametinib, unknown these outcomes have not yet been studied. This case series compared cognition behavior eight PLGG cases prior to while on treatment trametinib four controls. Intelligence the was mainly unchanged treatment, mild decline one seven complete data. Parent-reported depression symptoms increased five relative